earnings
confidence high
sentiment positive
materiality 0.80
Niagen Bioscience Q3 net sales up 33% to $34M, net income $4.6M, raises FY sales growth outlook to 25-30%
Niagen Bioscience, Inc.
2025-Q3 EPS reported
$0.15
revenue$95,584,000
- Net sales $34.0M (+33% YoY); Tru Niagen sales $26.0M (+44% YoY).
- Net income $4.6M ($0.06 EPS) vs $1.9M ($0.02 EPS) prior year; adjusted EBITDA $6.4M (+120%).
- Gross margin 64.5% (+100 bps); sales & marketing expense as % of sales improved 170 bps to 25.8%.
- New FY 2025 outlook: net sales growth 25-30% (from 22-27%); reaffirms momentum in Tru Niagen and Niagen ingredients.
- Operational: launched AboutNAD platform, won NAD+ advertising challenge, expanded clinic network to 1,000+ sites.